Trial · NCT03087019
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Patients Demonstrating Objective Response In Non-Irradiated Lesions (Tumor Size on Scans) | Pembrolizumab + Radiation | 0 | Participants | ||
| Patients Demonstrating Objective Response In Non-Irradiated Lesions (Tumor Size on Scans) | Pembrolizumab | 0 | Participants | ||
| Progression Free Survival (Time From Randomization to Disease Progression or Death) | Pembrolizumab + Radiation | 4.5 | 95% Confidence Interval 2.4 to 20.6 | months | |
| Progression Free Survival (Time From Randomization to Disease Progression or Death) | Pembrolizumab | 6.6 | 95% Confidence Interval 2.4 to 13.1 | months | |
| Overall Survival (Time From Randomization to Death) | Pembrolizumab + Radiation | NA | 95% Confidence Interval 10.1 to NA | months | |
| Overall Survival (Time From Randomization to Death) | Pembrolizumab | 27.2 | 95% Confidence Interval 22.9 to NA | months | |
| Number of Participants With Complete Response (Absence of Non-irradiated Lesions on Scans) | Pembrolizumab + Radiation | 0 | Participants | ||
| Number of Participants With Complete Response (Absence of Non-irradiated Lesions on Scans) | Pembrolizumab | 0 | Participants | ||
| Number of Participants With Partial Response (Tumor Size on Scans) | Pembrolizumab + Radiation | 0 | Participants | ||
| Number of Participants With Partial Response (Tumor Size on Scans) | Pembrolizumab | 0 | Participants | ||
| Number of Treatment-Emergent Adverse Events | Pembrolizumab + Radiation | 51 | treatment-emergent adverse events | ||
| Number of Treatment-Emergent Adverse Events | Pembrolizumab | 24 | treatment-emergent adverse events |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03087019/results